Irina Rebin

Prix à l'honneur

JUVE Awards 2023

Law firm of the year for IP Law

Irina is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group. Her practice includes advising pharmaceutical, medical device, and biotechnology companies and investors on all regulatory matters throughout the entire life cycle of medicinal products, medical devices, and IVDs: from preclinical research and clinical trials, manufacturing, and market access to distribution (including post-market surveillance).

She also provides legal advice on genetic engineering, food (including food supplements), and cosmetics. Irina complements this practice focus by drafting and negotiating corresponding industry-specific agreements (including research and development agreements, license agreements, clinical trial agreements, contract/manufacturing and distribution agreements (including quality agreements)) and by advising on (cross-border) transactions in the healthcare sector.

CV

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

Carrière

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

Formation

2019 Second state examination, Munich

2014 – 2017 Doctoral studies at Ludwig Maximilians University Munich

2014 - 2015 Doctoral studies at Georg August University Göttingen

Publications

§§ 40-42e AMG in: Rehmann, AMG, 6. Aufl. [in Bearb./vor. Anfang 2026] § 15 Entwicklung des Arzneimittelprüfrechts

§ 16 Grundlagen klinischer Arzneimittelprüfungen

§ 17 Zentrale Voraussetzungen klinischer Prüfungen im Überblick in: Spickhoff/Handorn: Handbuch Medizinisches Forschungsrecht, C. H. Beck, München, 2023

§ 2 ProdHaftG im Beck-Online-Großkommentar (seit 2015)

Langues étrangères

Prix et distinctions

JUVE Awards 2023

Featured

Actualités et publications récentes

View Irina's insights

Cliquer ici pour en savoir plus

Sciences de la vie et Santé

The 2026 Pharma Package: A New Regulatory Framework for Medicinal Products in the EU

15 avril 2026

par Irina Rebin

International Life Sciences Newsletter - Life Sciences Legal Lens Vol 1

Impact of the new Biotech Act on Clinical Trials in the EU

A European Perspective #1 | EU Biotech Act: Faster Clinical Trial Approvals Ahead | The European Commission’s proposed Biotech Act aims to streamline clinical trial procedures, shorten approval timelines, and harmonise data protection rules across the EU. If adopted, the reform could significantly accelerate multinational clinical research in the EU.

15 avril 2026

Quick read

par Irina Rebin

4 de 9 Publications

Cliquer ici pour en savoir plus

International Life Sciences Newsletter - Life Sciences Legal Lens Vol 1

No claim for damages as a result of participation in clinical drug trials

A European Perspective #1 | GERMANY | The Frankfurt am Main Regional Court confirms: No reduction in the burden of proof (presumption of causality) pursuant to Section 84 (2) of the German Medicines Act (AMG) for IMP (not even by analogy) and no liability on the part of the sponsor in the event of (insufficient) risk information provided by the investigating physician.

1 avril 2026

par Irina Rebin

7 de 9 Publications

Cliquer ici pour en savoir plus

Irina Rebin

JUVE Awards 2023

Expertise

Services et Groupes

Secteurs

CV

Carrière

Formation

Publications

Langues étrangères

Prix et distinctions

JUVE Awards 2023

Actualités et publications récentes

The 2026 Pharma Package: A New Regulatory Framework for Medicinal Products in the EU

Irina Rebin

JUVE Awards 2023

Expertise

Services et Groupes

Secteurs

CV

Carrière

Formation

Publications

Langues étrangères

Prix et distinctions

JUVE Awards 2023

Actualités et publications récentes

The 2026 Pharma Package: A New Regulatory Framework for Medicinal Products in the EU

Related news & insights

Cyber Resilience Act and Franchise Networks: Hidden Duties for “Digital” Franchisors

Physical AI in the Digital Omnibus – Update

Guidelines for high-risk AI systems

The AI Boom Meets Regulation: Mandatory EU Labeling for Data Centers

EU authorized new sanctions against Russia

New Court, new approaches: How the UPC is reshaping pharmaceutical patent litigation

PPWR & Distribution/Franchising: Packaging compliance as a strategic necessity

Cabinet decision on the Statutory Health Insurance Contribution Stabilization Act – Financial burdens on German pharmaceutical companies

Federal Administrative Court on the Delineation between Substance-Based Medical Devices and Medicinal Products

CJEU Advocate General on Distributors’ Obligations for Medical Devices

Autres avocats qui pourraient vous intéresser

Rendez-vous à